Prevalence of obesity and type 2 diabetes (T2D) is skyrocketing across the globe and most importantly, the number of affected people continues to climb, also among children. This scenario results mainly from the adoption of poor lifestyle habits and exposure to environmental factorssuch as pollution, cigarette smoking, and urban noise-during the course of life.
The development of cardiometabolic features namely, low-grade inflammation, insulin resistance, and dysglycaemia is strongly associated with cardiovascular morbidity and mortality. Hence, a better understanding of the interplay between maladaptive metabolic processes and cardiovascular disease is of paramount importance for the development of new therapeutic approaches to fight the growing burden of cardiometabolic diseases.
The research group of Professor Francesco Paneni at the Center for Molecular Cardiology, University of Zurich, is actively involved in understanding the molecular clues underpinning cardiac and vascular damage in the setting of obesity and T2D (Figure 1) . The main goal of Paneni's lab is to unveil novel molecular targets for the development of personalized therapies in this setting. New data from his lab were recently presented by Sarah Costantino, senior research associate, at the Annual Meeting of the American Heart Association held in Philadelphia in November 2019.
Dr Costantino has recently unveiled a new molecular target involved in obesity-related endothelial dysfunction. In human endothelial cells, transgenic mice as well as in human vessels from obese patients, she demonstrated a pivotal role for the scaffolding protein merlin in regulating nitric oxide synthase (eNOS). Obesity-induced activation of merlin fostered the interaction of Caveolin-1 with eNOS, thus leading to reduced nitric oxide levels and endothelial dysfunction. In contrast, endothelial-specific deletion of merlin was able to prevent vascular dysfunction in obese mice. Of clinical relevance, merlin signalling was strongly activated in visceral fat arteries isolated from obese patients and correlated with endothelial dysfunction. The present work, performed in collaboration with the UCLA University (USA) and the University of Pisa (Italy), suggests that targeting merlin in the vascular endothelium may represent a potential strategy to alleviate vascular disease in cardiometabolic patients. This study was evaluated as the highest-ranked abstract from Switzerland and its scientific value was recognized with the prestigious Paul Dudley White International Scholar Award to Sarah Costantino first author of the submitted abstract. These promising results may pave the way for new molecular therapies to prevent vascular damage in patients with cardiometabolic disturbances. 
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